Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.
about
Protease expression by microorganisms and its relevance to crucial physiological/pathological eventsDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Leishmaniasis: new approaches to disease control.Importance of nonenteric protozoan infections in immunocompromised people.Balancing immunity and pathology in visceral leishmaniasis.Parasitic infections in HIV infected individuals: diagnostic & therapeutic challengesMethods of Control of the Leishmania infantum Dog Reservoir: State of the Art.Risk Factors for Death from Visceral Leishmaniasis in an Urban Area of Brazil.Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study.Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.The relationship between leishmaniasis and AIDS: the second 10 yearsMagnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review.Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example.Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment.Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis.Leishmaniasis: new insights from an old and neglected disease.Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil.Incidences of canine leishmaniasis in an endemic area of southern Italy.Successful therapeutic splenectomy in an HIV patient with relapsing visceral leishmaniasis.High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil.Crystal structure of the retroviral protease-like domain of a protozoal DNA damage-inducible 1 protein
P2860
Q28477918-9264ACCC-F7CE-4331-BC4E-BD60E52AFC9CQ30275257-0A38479E-632C-4E15-A8F1-6B33BEF99B42Q33813871-871F5EB4-F89B-4C38-94ED-A4E4E2E325B6Q34189873-8855222C-74BD-4F8E-863D-AC5104B2B2E0Q34587432-4CE4D6ED-2BDF-4231-A5BD-8B741E8C1859Q34635675-811D7BDB-56CC-44AE-97D0-68D2D4CEFAF0Q35101238-B47516D5-4789-4CDB-94D0-762519E1AD3FQ35746358-78EA3EFF-E146-4BF5-B47B-07C5532CE3BDQ36284391-BBE82406-4494-47F1-9FAC-CFEE60B0FE3AQ36328956-C5C6C74F-1D13-46C5-842A-EB62097F60CEQ36538814-C10899ED-5C9B-448E-B1C6-CFAC801F13DBQ36733559-B59B5480-FD93-4394-87D3-9544D19707D6Q37118101-A091A964-E2A9-4D05-8100-6D90904A61F2Q37544514-C645A59F-0456-491E-9675-4D915C12B609Q37548316-59B6CE3A-F527-4E90-84D6-339E49E195ACQ37870821-04C826F7-33A2-4BD4-9550-AAB7EF4AD235Q42072580-5C6B158C-80BF-49AA-A03B-4747D48E8702Q42225232-409A74E2-4FF8-4368-95C9-1E0A28E547CEQ45253497-1EA7B371-0D93-4312-883F-AB60A5978443Q54310101-0F61A35B-CB50-46C8-A0F3-BF1530BFB9CCQ54323269-0BA1D52B-6AA8-4CCD-B687-5C8412542324Q58801007-8C5AE36B-3660-4627-AC4A-49AA322B4CD5
P2860
Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Incidence of and risk factors ...... active antiretroviral therapy.
@ast
Incidence of and risk factors ...... active antiretroviral therapy.
@en
type
label
Incidence of and risk factors ...... active antiretroviral therapy.
@ast
Incidence of and risk factors ...... active antiretroviral therapy.
@en
prefLabel
Incidence of and risk factors ...... active antiretroviral therapy.
@ast
Incidence of and risk factors ...... active antiretroviral therapy.
@en
P2093
P2860
P1476
Incidence of and risk factors ...... active antiretroviral therapy.
@en
P2093
Armando Sánchez-Quijano
Eduardo Lissen
Francisco Morillas
José A Mira
Juan A Pineda
Juan Delgado
Juan Macías
Manuel Leal
Rafael de La Rosa
P2860
P304
P356
10.1128/JCM.40.3.762-767.2002
P407
P577
2002-03-01T00:00:00Z